Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase of Trypanosoma brucei

Journal of Biological Chemistry

Volumn 288, Issue 38, 2013, Pages 27456-27468

  Lu, Jun ^a   Vodnala, Suman K ^a   Gustavsson, Anna Lena ^b   Gustafsson, Tomas N ^a   Sjöberg, Birger ^b   Johansson, Henrik A ^a,c   Kumar, Sangit ^d   Tjernberg, Agneta ^e   Engman, Lars ^c   Rottenberg, Martin E ^a   Holmgren, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH BHOPAL   (India)

^e BIOVITRUM AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NON-PROTEIN THIOLS; POTENT INHIBITOR; REACTIVE OXYGEN SPECIES; SELECTIVITY INDEX; SULFUR ANALOGUES; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; TRYPANOTHIONE REDUCTASE;

OXYGEN; REDOX REACTIONS;

ENZYME ACTIVITY;

1,2 BENZISOTHIAZOLE DERIVATIVE; CATALASE; DNA; EBSELEN; EBSULFUR; GLUCOSE OXIDASE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; NIFURTIMOX; REACTIVE OXYGEN METABOLITE; SULFUR DERIVATIVE; TRYPANOTHIONE; TRYPANOTHIONE REDUCTASE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DETOXIFICATION; DNA SYNTHESIS; DRUG STRUCTURE; EPIMASTIGOTE; IC 50; LEISHMANIA MAJOR; MALE; MAMMAL CELL; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMA RHODESIENSE;

DRUG DEVELOPMENT; ENZYME INHIBITORS; PARASITE; REACTIVE OXYGEN SPECIES (ROS); THIOL; THIOREDOXIN;

ANIMALS; MALE; MICE; NADH, NADPH OXIDOREDUCTASES; PLATELET AGGREGATION INHIBITORS; PROTOZOAN PROTEINS; THIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 84884583041     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.495101     Document Type: Article

References (52)

1. Dumas, M., and Bisser, S. (1999) in Progress in Human African Trypanosomiasis, Sleeping Sickness (Dumas, M., Bouteille, B., and Buguet, A., eds) pp. 215-233, Springer, Paris
2. Kibona, S. N., Matemba, L., Kaboya, J. S., and Lubega, G. W. (2006) Drugresistance of Trypanosoma b. rhodesiense isolates from Tanzania. Trop. Med. Int. Health 11, 144-155
3. Kristensson, K., Mhlanga, J. D., and Bentivoglio, M. (2002) Parasites and the brain: neuroinvasion, immunopathogenesis and neuronal dysfunctions. Curr. Top. Microbiol. Immunol. 265, 227-257
4. Masocha, W., Robertson, B., Rottenberg, M. E., Mhlanga, J., Sorokin, L., and Kristensson, K. (2004) Cerebral vessel laminins and IFN-γ define Trypanosoma brucei brucei penetration of the blood-brain barrier. J. Clin. Invest. 114, 689-694
5. Fairlamb, A. H., and Cerami, A. (1992) Metabolism and functions of trypanothione in the Kinetoplastida. Annu. Rev. Microbiol. 46, 695-729
6. Fairlamb, A. H., Blackburn, P., Ulrich, P., Chait, B. T., and Cerami, A. (1985) Trypanothione: a novel bis (glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science 227, 1485-1487
7. Krauth-Siegel, R. L., and Leroux, A. E. (2012) Low-molecular-mass antioxidants in parasites. Antioxid. Redox Signal. 17, 583-607
8. Krieger, S., Schwarz, W., Ariyanayagam, M. R., Fairlamb, A. H., Krauth-Siegel, R. L., and Clayton, C. (2000) Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol. 35, 542-552
9. Comini, M. A., Krauth-Siegel, R. L., and Flohé, L. (2007) Depletion of the thioredoxin homologue tryparedoxin impairs antioxidative defence in African trypanosomes. Biochem. J. 402, 43-49
10. Krauth-Siegel, R. L., and Comini, M. A. (2008) Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochim. Biophys. Acta 1780, 1236-1248
11. Ceylan, S., Seidel, V., Ziebart, N., Berndt, C., Dirdjaja, N., and Krauth-Siegel, R. L. (2010) The dithiol glutaredoxins of African trypanosomes have distinct roles and are closely linked to the unique trypanothione metabolism. J. Biol. Chem. 285, 35224-35237
12. Schmidt, A., and Krauth-Siegel, R. L. (2002) Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr. Top. Med. Chem. 2, 1239-1259
13. Olin-Sandoval, V., Moreno-Sánchez, R., and Saavedra, E. (2010) Targeting trypanothione metabolism in trypanosomatid human parasites. Curr. Drug. Targets 11, 1614-1630
14. Spinks, D., Shanks, E. J., Cleghorn, L. A., McElroy, S., Jones, D., James, D., Fairlamb, A. H., Frearson, J. A., Wyatt, P. G., and Gilbert, I. H. (2009) Investigation of trypanothione reductase as a drug target in Trypanosoma brucei. Chem. Med. Chem. 4, 2060-2069
15. Fairlamb, A. H., Henderson, G. B., and Cerami, A. (1989) Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 86, 2607-2611
16. Wyllie, S., Cunningham, M. L., and Fairlamb, A. H. (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem. 279, 39925-39932
17. Richardson, J. L., Nett, I. R., Jones, D. C., Abdille, M. H., Gilbert, I. H., and Fairlamb, A. H. (2009) Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. Chem. Med. Chem. 4, 1333-1340
18. Benson, T. J., McKie, J. H., Garforth, J., Borges, A., Fairlamb, A. H., and Douglas, K. T. (1992) Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures.
19. Patterson, S., Alphey, M. S., Jones, D. C., Shanks, E. J., Street, I. P., Frearson, J. A., Wyatt, P. G., Gilbert, I. H., and Fairlamb, A. H. (2011) Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallography. J. Med. Chem. 54, 6514-6530
20. Saravanamuthu, A., Vickers, T. J., Bond, C. S., Peterson, M. R., Hunter, W. N., and Fairlamb, A. H. (2004) Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design. J. Biol. Chem. 279, 29493-29500
21. Bonse, S., Santelli-Rouvier, C., Barbe, J., and Krauth-Siegel, R. L. (1999) Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships. J. Med. Chem. 42, 5448-5454
22. Meiering, S., Inhoff, O., Mies, J., Vincek, A., Garcia, G., Kramer, B., Dormeyer, M., and Krauth-Siegel, R. L. (2005) Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. J. Med. Chem. 48, 4793-4802
23. Schewe, T. (1995) Molecular actions of ebselen-an antiinflammatory antioxidant. Gen. Pharmacol. 26, 1153-1169
24. Zhao, R., Masayasu, H., and Holmgren, A. (2002) Ebselen: A substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc. Natl Acad. Sci. U. S. A. 99, 8579-8584
25. Zhao, R., and Holmgren, A. (2002) A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. J. Biol. Chem. 277, 39456-39462
26. Nozawa, R., Yokota, T., and Fujimoto, T. (1989) Susceptibility of methicillinresistant Staphylococcus aureus to the selenium-containing compound 2-phenyl-1, 2-benzoisoselenazol-3 (2H)-one (PZ51). Antimicrob. Agents Chemother. 33, 1388-1390
27. Lu, J., Vlamis-Gardikas, A., Kandasamy, K., Zhao, R., Gustafsson, T. N., Engstrand, L., Hoffner, S., Engman, L., and Holmgren, A. (2013) Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J. 27, 1394-1403
28. Gustafsson, T. N., Sahlin, M., Lu, J., Sjöberg, B. M., and Holmgren, A. (2012) Bacillus anthracis thioredoxin systems, characterization and role as electron donors for ribonucleotide reductase. J. Biol. Chem. 287, 39686-39697
29. Gustafsson, T. N., Sandalova, T., Lu, J., Holmgren, A., and Schneider, G. (2007) High-resolution structures of oxidized and reduced thioredoxin reductase from Helicobacter pylori. Acta Crystallogr. D Biol. Crystallogr. 63, 833-843
30. Engman, L., and Hallberg, A. (1989) Expedient synthesis of ebselen and related-compounds. J. Org. Chem. 54, 2964-2966
31. Mlochowski, J., Kloc, K., Syper, L., Inglot, A. D., and Piasecki, E. (1993) Aromatic and azaaromatic diselenides, benzisoselenazolones, and relatedcompounds as immunomodulators active in humans-Synthesis and properties. Liebigs Annalen Der. Chemie, 1239-1244
32. Wójtowicz, H., Kloc, K., Maliszewska, I., Mlóchowski, J., Pietka, M., and Piasecki, E. (2004) Azaanalogues of ebselen as antimicrobial and antiviral agents: synthesis and properties. Farmaco 59, 863-868
33. Holmgren, A., Lu, J., Vlamis-Gardikas, A., Zhao, R., Kandasamy, K., Engman, L., Engstrand, L., and Hoffner, S. (May 22, 2007) Bacterial thioredoxin reductase inhibitors and methods for use thereof. U. S. Patent Appl. 2011/2088, 130
34. He, J., Li, D., Xiong, K., Ge, Y., Jin, H., Zhang, G., Hong, M., Tian, Y., Yin, J., and Zeng, H. (2012) Inhibition of thioredoxin reductase by a novel series of bis-1, 2-benzisoselenazol-3 (2H)-ones: Organoselenium compounds for cancer therapy. Bioorg. Med. Chem. 20, 3816-3827
35. Ranganathan, S., Muraleedharan, K. M., Bharadwaj, P., Chatterji, D., and Karle, I. (2002) The design and synthesis of redox core-α amino acid composites based on thiol-disulfide exchange mechanism and a comparative study of their zinc abstraction potential from [CCXX] boxes in proteins. Tetrahedron 58, 2861-2874
36. Bhakuni, B. S., Balkrishna, S. J., Kumar, A., and Kumar, S. (2012) An efficient copper-mediated synthetic methodology for benzo[d]isothiazol-3 (2H)-ones and related sulfur-nitrogen heterocycles. Tetrahedron Lett. 53, 1354-1357
37. Homburg, C. H., De Haas, M., Von Dem Borne, A. E., Verhoeven, A. J., Reutelingsperger, C. P., and Roos, D. (1995) Human neutrophils lose their surface Fcγ RIII and acquire annexin V-binding sites during apoptosis in vitro. Blood 85, 532-540
38. Tsuda, A., Witola, W. H., Konnai, S., Ohashi, K., and Onuma, M. (2006) The effect of TAO expression on PCD-like phenomenon development and drug resistance in Trypanosoma brucei. Parasitol. Int. 55, 135-142
39. Welburn, S. C., Macleod, E., Figarella, K., and Duzensko, M. (2006) Programmed cell death in African trypanosomes. Parasitology 132, S7-S18
40. Jones, D. C., Ariza, A., Chow, W. H., Oza, S. L., and Fairlamb, A. H. (2010) Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi. Mol. Biochem. Parasitol. 169, 12-19
41. Kitz, R., and Wilson, I. B. (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 237, 3245-3249
42. Urbina, J. A., and Docampo, R. (2003) Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 19, 495-501
43. Cerecetto, H., and González, M. (2011) Antiparasitic prodrug nifurtimox: revisiting its activation mechanism. Future Microbiol. 6, 847-850
44. Dahl, R., Bravo, Y., Sharma, V., Ichikawa, M., Dhanya, R. P., Hedrick, M., Brown, B., Rascon, J., Vicchiarelli, M., Mangravita-Novo, A., Yang, L., Stonich, D., Su, Y., Smith, L. H., Sergienko, E., Freeze, H. H., and Cosford, N. D. (2011) Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J. Med. Chem. 54, 3661-3668
45. Hunter, W. N., Bailey, S., Habash, J., Harrop, S. J., Helliwell, J. R., Aboagye-Kwarteng, T., Smith, K., and Fairlamb, A. H. (1992) Active site of trypanothione reductase. A target for rational drug design. J. Mol. Biol. 227, 322-333
46. Sharlow, E. R., Lyda, T. A., Dodson, H. C., Mustata, G., Morris, M. T., Leimgruber, S. S., Lee, K. H., Kashiwada, Y., Close, D., Lazo, J. S., and Morris, J. C. (2010) A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl. Trop. Dis. 4, e659
47. Wilkinson, S. R., Horn, D., Prathalingam, S. R., and Kelly, J. M. (2003) RNA interference identifies two hydroperoxide metabolizing enzymes that are essential to the blood stream form of the African trypanosome. J. Biol. Chem. 278, 31640-31646
48. Schlecker, T., Schmidt, A., Dirdjaja, N., Voncken, F., Clayton, C., and Krauth-Siegel, R. L. (2005) Substrate specificity, localization, and essential role of the glutathione peroxidase-type tryparedoxin peroxidases in Trypanosoma brucei. J. Biol. Chem. 280, 14385-14394
49. Krauth-Siegel, R. L., and Schöneck, R. (1995) Flavoprotein structure and mechanism. 5. Trypanothione reductase and lipoamide dehydrogenase as targets for a structure-based drug design. FASEB J. 9, 1138-1146
50. Arrick, B. A., Griffith, O. W., and Cerami, A. (1981) Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis. J. Exp. Med. 153, 720-725
51. Tovar, J., Cunningham, M. L., Smith, A. C., Croft, S. L., and Fairlamb, A. H. (1998) Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival. Proc. Natl. Acad. Sci. U. S. A. 95, 5311-5316
52. Dumas, C., Ouellette, M., Tovar, J., Cunningham, M. L., Fairlamb, A. H., Tamar, S., Olivier, M., and Papadopoulou, B. (1997) Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J. 16, 2590-2598